Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.
| Save | Drug · Modality · Trial | Indication | Headline | Flags | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
APR 302026 todayEXACT 8-K15d ago | IMVT $5.7B | Conf. | 0.464/6 | — | 0 first | batoclimab mAb · anti-FcRn mAb | Myasthenia Gravis | Batoclimab Open-Label Extension Data — AAN 2026 | |||
MAY–MAY2026 4 daysWINDOW PR1mo ago | CRBU $240M | Conf. | 0.242/6 | −$1.1M 0b · 4s | 0 first | CB-010 cell therapy · allogeneic CRISPR-edited anti-CD19 CAR-T NCT05023239n=75 | B-cell Non-Hodgkin Lymphoma | CB-010 ANTLER Dose-Expansion Cohort — ASGCT 2026 | |||
MAY 062026 6 daysEXACT PR21d ago | AKRO $2.4B | Conf. | 0.588/11 | +$566K 4b · 1s | 0 first | efruxifermin biologic · FGF21 analog Fc-fusion NCT04880421n=1,650 | MASH (NASH) | Efruxifermin Cirrhotic MASH Data — EASL Congress | |||
MAY 082026 8 daysEXACT PR5d ago | AXSM $4.2B | Readout | 0.588/11 | −$276K 0b · 1s | 0 first | AUVELITY small molecule · NMDA antagonist + sigma-1 agonist | Major Depressive Disorder | AUVELITY Adolescent MDD Phase 3 Topline | Pro | ||
MAY–MAY2026 12 daysWINDOW PR18d ago | EDIT $380M | Conf. | 0.285/12 | −$2.6M 0b · 4s | 0 first | reni-cel cell therapy · CRISPR/Cas12a HBG1/2 promoter edit NCT05444894n=30 | Sickle Cell Disease | reni-cel RUBY Long-term Follow-up — ASGCT 2026 | |||
MAY 152026 15 daysEXACT PR9d ago | ARWR $2.2B | Conf. | 0.464/6 | −$381K 1b · 3s | 0 first | plozasiran siRNA · APOC3-targeting RNAi NCT06028386n=110 | Familial Chylomicronemia | Plozasiran Long-term Open-Label Data — EAS Congress | |||
MAY 222026 22 daysEXACT FDA1mo ago | SRPT $2.8B | AdCom | 0.474/6 | −$2.0M 2b · 3s | 0 first | ELEVIDYS gene therapy · AAVrh74-microdystrophin transfer | Duchenne Muscular Dystrophy | ELEVIDYS sBLA Cellular, Tissue, and Gene Therapies AdCom |
Including BPMC · AYVAKIT · Conf. · MAY–MAY 2026 and 5 others. Free tier shows the next 14 days; upgrade to unlock the full 12-month calendar with date-slip alerts.